Publication: Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer
7
Issued Date
2020-12-01
Resource Type
ISSN
18734367
09277765
09277765
Other identifier(s)
2-s2.0-85089069123
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Colloids and Surfaces B: Biointerfaces. Vol.196, (2020)
Suggested Citation
Paweena Dana, Suphawadee Bunthot, Kunat Suktham, Suvimol Surassmo, Teerapong Yata, Katawut Namdee, Werayut Yingmema, Thunyatorn Yimsoo, Uracha Rungsardthong Ruktanonchai, Sith Sathornsumetee, Nattika Saengkrit Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. Colloids and Surfaces B: Biointerfaces. Vol.196, (2020). doi:10.1016/j.colsurfb.2020.111270 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/57666
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer
Abstract
© 2020 Elsevier B.V. Cisplatin (Cis) is a widely used chemotherapeutic drug for cancer treatment. However, toxicities and drug resistance limit the use of cisplatin. This study was aimed to improve cisplatin delivery using a targeting strategy to reduce the toxicity. In the present study, combinations of poly lactic-co-glycolic acids (PLGA) and liposomes were used as carriers for cisplatin delivery. In addition, to target the nanoparticle towards tumor cells, the liposome was conjugated with Avastin®, an anti-VEGF antibody. Cisplatin was loaded into PLGA using the double emulsion solvent evaporation method and further encapsulated in an Avastin® conjugated liposome (define herein as L-PLGA-Cis-Avastin®). Their physicochemical properties, including particle size, ζ-potential, encapsulation efficiency and drug release profiles were characterized. In addition, a study of the efficiency of tumor targeted drug delivery was conducted with cervical tumor bearing mice via intravenous injection. The therapeutic effect was examined in a 3D spheroid of SiHa cell line and SiHa cells bearing mice. The L-PLGA-Cis-Avastin® prompted a significant effect on cell viability and triggered cytotoxicity of SiHa cells. A cell internalization study confirmed that the L-PLGA-Cis-Avastin® had greater binding specificity to SiHa cells than those of L-PLGA-Cis or free drug, resulting in enhanced cellular uptake. Tumor targeting specificity was finally confirmed in xenograft tumors. Taken together, this nanoparticle could serve as a promising specific targeted drug for cervical cancer treatment.